Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS.
J Cardiovasc Pharmacol. 2022 Aug 1;80(2):206-209. doi: 10.1097/FJC.0000000000001300.
Septic shock is life-threatening organ dysfunction due to a dysregulated response to infection. It is a leading cause of death caused by the excessive release of cytokines and inflammatory mediators in response to bacterial endotoxins. It produces hypotension refractory to vasoconstrictors leading to tissue hypoperfusion and multiple organ failure. Despite intensive investigation, there still are no specific pharmacologic treatments. Current therapy relies on supportive care, including antibiotics, fluid resuscitation, corticosteroids, and pressor agents. This commentary summarizes little-known previous observations that inhibition of vascular 20-hydroxyeicosatetraenoic acid (20-HETE) by nitric oxide plays a key role in sepsis. It also highlights the new and exciting current report by Tunctan et al (2022) in this issue of Journal of Cardiovascular Pharmacology that administration of a 20-HETE mimetic can prevent lipopolysaccharide-induced vascular hyporeactivity, hypotension, and tachycardia in rats by activating the recently discovered GPR75/20-HETE receptor. Overall, these results provide a compelling case for initiating 20-HETE clinical trials to prevent hypotension, multiple organ failure, and death in septic shock.
感染导致的失控反应会引起脓毒性休克,进而危及生命,导致器官功能障碍。这是一种由细菌内毒素引起的细胞因子和炎症介质过度释放导致的主要死亡原因。它会导致低血压,对血管收缩剂产生抗性,从而导致组织灌注不足和多器官衰竭。尽管进行了深入研究,但目前仍没有特定的药物治疗方法。目前的治疗方法依赖于支持性护理,包括抗生素、液体复苏、皮质类固醇和升压药。本评论总结了以前鲜为人知的观察结果,即一氧化氮抑制血管 20-羟二十碳四烯酸(20-HETE)在脓毒症中起着关键作用。它还强调了 Tunctan 等人在本期《心血管药理学杂志》上的最新令人兴奋的报告,即通过激活最近发现的 GPR75/20-HETE 受体,给予 20-HETE 类似物可以预防脂多糖诱导的大鼠血管反应性降低、低血压和心动过速。总的来说,这些结果为启动 20-HETE 临床试验提供了强有力的依据,以预防脓毒性休克中的低血压、多器官衰竭和死亡。